TCF — Theracryf Share News
0.000.00%
Last trade - 00:00Holding(s) in Company
Australian partner to progress Ox-1 Phase 1 trial
Posting of Annual Report and Notice of AGM
Final Results for the year ended 31 March 2026
Notice of Results and Investor Presentation
Holding(s) in Company
Holding(s) in Company
Proposed Placing & Subscription to raise £1.05m
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Positive Ox-1 tox data in addiction programme
Investor Webinar
Successful GMP Manufacture Advances Ox-1 to Clinic
New Manufacturing Process Patent for Ox-1
Brief: TheraCryf Receives Non-Binding Proposal To Acquire TheraCryf’s Assets
Non-Binding Proposal to Acquire TheraCryf’s Assets
Brief: Theracryf's Ox-1 Programme Advances To Final Toxicology Study